Literature DB >> 22089161

Antinucleosome in systemic lupus erythematosus. A study in a Brazilian population.

G A Sardeto1, L M Simas, T S Skare, R M Nisihara, S R R Utiyama.   

Abstract

Antinucleosome antibodies have been found with variable prevalence in systemic lupus erythematosus (SLE) and were associated with more severe disease. This research aims to study the prevalence of antinucleosome antibodies in a sample of Brazilian adult SLE patients and their association with clinical findings and disease activity. Ninety-two adult patients (81 females and 11 males, with mean age of 37.29 ± 10.98 years) with SLE were studied for clinical and antibody profile, disease activity by SLE disease activity index (SLEDAI), and presence of antinucleosome antibodies by ELISA. The prevalence of antinucleosome antibodies was 61.9% (mean titer, 87.8 ± 62.6 U). No relationship was found of antinucleosome presence and any of the studied clinical features. A positive association was detected with anti-DNA (p = 0.001) and SLEDAI (p < 0.0001), but not with anti-Sm, anti-Ro, anti-La, and anti-RNP. No specific disease feature could be associated with the presence of antinucleosome; however, a positive relationship was detected with disease activity measured by SLEDAI and with anti-DNA presence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089161     DOI: 10.1007/s10067-011-1889-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy.

Authors:  R Cervera; O Viñas; M Ramos-Casals; J Font; M García-Carrasco; A Sisó; F Ramírez; Y Machuca; J Vives; M Ingelmo; R W Burlingame
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

2.  Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus.

Authors:  L M A Campos; M H B Kiss; M A Scheinberg; C L P Mangueira; C A Silva
Journal:  Lupus       Date:  2006       Impact factor: 2.911

3.  An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study.

Authors:  C T Ravirajan; L Rowse; J R MacGowan; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

4.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

Review 5.  Anti-chromatin (anti-nucleosome) antibodies.

Authors:  J A Gómez-Puerta; R W Burlingame; R Cervera
Journal:  Lupus       Date:  2006       Impact factor: 2.911

6.  Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients.

Authors:  P Ghillani-Dalbin; Z Amoura; P Cacoub; J L Charuel; M C Diemert; J C Piette; L Musset
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 7.  Pathogenic anti-nucleosome antibodies.

Authors:  S Muller; J Dieker; A Tincani; P L Meroni
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

8.  Antinucleosome antibodies and systemic lupus erythematosus.

Authors:  Nurşen Düzgün; Mehmet Sahin; Yasemin Genç; Hüseyin Tutkak
Journal:  Ann N Y Acad Sci       Date:  2007-08       Impact factor: 5.691

9.  Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients.

Authors:  A Ghirardello; A Doria; S Zampieri; E Tarricone; R Tozzoli; D Villalta; N Bizzaro; A Piccoli; P F Gambari
Journal:  J Autoimmun       Date:  2004-05       Impact factor: 7.094

10.  Anti-nucleosome antibody in sclerodema patients.

Authors:  Francisco Gustavo Mendes E Ferreira de Araujo; Thelma Larocca Skare; Renato M Nisihara; Shirley R Utiyama
Journal:  Indian J Med Res       Date:  2011-03       Impact factor: 2.375

View more
  3 in total

1.  New evidence for roles of antinucleosome antibodies in systemic lupus erythematosus.

Authors:  De-Guang Wang; Li Hao; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2011-12-28       Impact factor: 2.980

Review 2.  Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?

Authors:  Kevin Didier; Loïs Bolko; Delphine Giusti; Segolene Toquet; Ailsa Robbins; Frank Antonicelli; Amelie Servettaz
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

Review 3.  The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.

Authors:  Sonal Mehra; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-03       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.